Could an HIV drug tame brain inflammation in Alzheimer's?

NCT ID NCT07553338

Recruiting now Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a drug called leronlimab is safe for people with mild Alzheimer's or mild cognitive impairment. Twenty volunteers over age 50 will receive weekly injections for 12 weeks. Researchers will use brain scans and blood tests to see if the drug lowers brain inflammation, which is thought to play a role in Alzheimer's. This is the first time leronlimab is being tested in Alzheimer's patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: leronlimab (a lab-made antibody)
What this could lead to: If it works, this could point toward a treatment that slows Alzheimer's by reducing brain inflammation.
What could go wrong: This is a very small, early-phase trial focused on safety, not effectiveness. The drug may not reduce inflammation or help thinking skills, and side effects are unknown in this group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE MILD COGNITIVE IMPAIRMENT (MCI) DUE TO ALZHEIMER'S DISEASE

Contacts and locations

Locations

Weill Cornell Medicine Brain Health Imaging Institute
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.